Wave Life Sciences shares plunge as data for high dose of obesity drug disappoints

Wave Life Sciences shares plunged over 55% on Thursday after a higher dose of its experimental ​obesity drug failed to show a clear improvement at ‌reducing a dangerous type of belly fat.